Collegium Pharma (COLL) Tops Q4 EPS by 62c

Collegium Pharma (NASDAQ: COLL) reported Q4 EPS of $0.27, $0.62 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $73.4 million versus the consensus estimate of $73.86 million.

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• Keefe, Bruyette & Woods Downgrades Sezzle Inc (SEZL) to Market Perform
• Mitsubishi Estate plans data center development by 2036